New chairman for Abacus Medicine

10 AUGUST 2020

After a number of years of high growth rates, Abacus Medicine is now further strengthening its board of directors. This will happen when Niels Smedegaard in two weeks’ time can look forward to being elected as the new chairman of the board when Abacus Medicine holds its annual general meeting on 26 August.

Niels Smedegaard is nominated by the two main shareholders in Abacus Medicine, which are Wagner Family Holding (59% ownership) and Chr. Augustinus Fabrikker (35% ownership).

Niels Smedegaard created great results as CEO of the shipping company DFDS from 2007-2019, and has since May 2019 been chairman of the board of the airline Norwegian. He is also a member of the board of among others DSV Panalpina, Falck and Royal Greenland.

“With his extensive and international experience, Niels Smedegaard has the right profile to contribute to Abacus Medicine’s continued growth in our ongoing globalization process. Niels has a sharp, analytical mind and a positive approach that matches well with our values, ”says Flemming Wagner, CEO and founder of Abacus Medicine.

Niels Smedegaard says: “I have already gained the first insight into the fantastic culture that has been created in Abacus Medicine. It is a strong foundation to build on. I am therefore very much looking forward to the further development and cooperation with the management, the employees and the other members of the board.”

At the same time, the two main shareholders recommend that Troels Peter Troelsen (75), current chairman of the board of Abacus Medicine A/S, continues as a non-executive board member. Since Troels Peter Troelsen joined the board in 2009, the turnover in Abacus Medicine has risen almost twentyfold – from approximately EUR 22 million to EUR 421 million euros in 2019.

Troels Peter Troelsen says: “Our development has been unique. It testifies to courage, vision and leadership culture beyond the ordinary. I am confident that Niels, as chairman, will be able to ensure that growth and earnings in Abacus Medicine will continue to be high and secure.”